Isn't this a relevant and responsible assessment of the risk in...

Isn't this a relevant and responsible assessment of the risk in the financial side of their operations that has always existed? I don't think that is anything new for anyone who has watched this company operate over the past few years.

In other words, as we all knew, if they don't manage to get approval for one or more of their products or ink a collaboration over the next 12 -18 months, then in reality what is the future of the company anyway?

The risk hasn't changed since the company started, the clock has always been ticking and the concept of their ability to continue as a going concern will always continue be relevant as they work through their processes to shore up approvals (as is the case of any biotech).
$116M cash + access to a finance facility is not chicken feed and there is a hell of a lot of action to come on several fronts in the next 6 months that will make things much clearer on their future (either + or -). Their outline of the risks throughout their Form 6K was thorough and appropriate due diligence, but doesn't mean the company will fail as your post seems to intimate.

Such is life with investment in medical companies.